On June 18, Moderna rose 7.23% in regular trading, trading at approximately $62.08/share, with turnover of $2.27 billion. The rally was driven by multiple positive catalysts converging simultaneously.

The core catalyst came from the FDA's review of Moderna's mRNA flu vaccine mFlusiva achieving significant progress. The FDA previously withdrew its rejection of the vaccine's initial application, and its advisory committee is set to vote on whether the vaccine's benefits outweigh risks in elderly populations. If approved, mFlusiva would become the first mRNA-based seasonal flu vaccine in the United States, offering faster production without reliance on traditional egg-based methods. FDA staff had noted in briefing documents that data showed strong immune responses, potentially supporting efficacy in adults aged 65 and older, with relative vaccine efficacy in the 50-64 age group superior to standard-dose flu vaccines.

Additionally, the company completed an organizational restructuring, appointing Ester Banque as Chief Commercial Officer to prepare for the launch of up to three new vaccines over the next two years. Moderna is also evaluating production facility investments in Germany to expand capacity for the European market.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)